Press Releases
Nacuity Pharmaceuticals, Inc. (Nacuity) today announced the initiation of a Phase 1/2 study of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). The study, named SLO-RP, is designed to demonstrate greater retinal sensitivity in RP/USH patients treated with NPI-001 Tablets versus placebo. Read more...
Nacuity Pharmaceuticals, Inc. (Nacuity) announces that it has entered into an agreement with Johns Hopkins University (JHU) providing Nacuity with an exclusive worldwide license to the intellectual property (IP) underlying certain U.S. and foreign patent applications that Nacuity has filed in collaboration with the Johns Hopkins Wilmer Eye Institute. Read more...
January 18, 2017
Press Release: "Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP"
The Foundation Fighting Blindness, the leading charitable institution driving research to provide treatments for people affected by RP and AMD, issues a press release announcing its technical and financial support of Nacuity Pharmaceuticals.
News
This post from the The Foundation Fighting Blindness announces that Nacuity is launching a Phase 1/2 clinical trial in Australia for NPI-001, an oral treatment designed to slow vision loss in people with retinitis pigmentosa (RP) and RP associated with Usher syndrome.
Nacuity Pharmaceuticals is featured in an article in The Adelaide Review as one of the pharmaceutical companies taking advantage of the financial and regulatory incentives provided by Adelaide, Australia, to bring clinical trials to their city.
September 27, 2017
"FFB’s Investments Are Filling the Pipeline for Vision-Saving Therapies"
Nacuity Pharmaceuticals CEO Halden Conner presented the company’s emerging drug N-Acetylcysteine Amide (NACA) at The Foundation Fighting Blindness' "Investing in Cures Summit" in Chicago, Illinois.
January 19, 2017
"Foundation Investing in Drug to Slow Many Forms of RP"
This post from the The Foundation Fighting Blindness' blog "Eye on the Cure" describes its investment in Nacuity Pharmaceuticals to advance RP treatment.
Publications
Neil J; Wall GM; Brown M. Antioxidant Effects of N-acetylcysteine Amide and NPI-002 on Human Skin or Equivalents. AAPS PharmSci360, Poster Abstract, October 26-November 5, 2020.
King B; Vance J; Wall GM; Shoup R. Quantitation of free and total N-acetylcysteine amide and its metabolite N-acetylcysteine in human plasma using derivatization and electrospray LC-MS/MS. J Chrom B 2019;1109:25-36.